Skip to main content

Table 2 ETEST performance based on FDA guidance

From: Contemporary analysis of ETEST for antibiotic susceptibility and minimum inhibitory concentration agreement against Pseudomonas aeruginosa from patients with cystic fibrosis

Antibiotic EA (%) CA (%) VME* No. (%) ME* No. (%) miE* No. (%) Recalculated miE** No. (%)
ATM 78 87 0 2 (3.3%) 13 (12.4%) 5 (4.8%)
FEP 72 64 0 5 (9.4%) 33 (31.4%) 13 (12.4%)
CAZ 82 91 1 (4.2%) 0 9 (8.6%) 3 (2.9%)
CZA 78 93 2 (18.2%)/0 (0.0%)* 5 (5.3%)/2 (2.1%)* ND ND
C/T 86 93 0 1 (1.4%) 6 (5.7%) 1 (1.0%)
CIP 79 8 0 0 16 (15.2%) 5 (4.8%)
LVX 63 83 0 0 18 (17.1%) 8 (7.6%)
MEM 86 91 0 2 (3.3%) 7 (6.7%) 3 (2.9%)
TZP 77 85 0 2 (2.9%) 14 (13.3%) 11 (10.5%)
TOB 82 81 0 1 (1.5%) 19 (18.1%) 6 (5.7%)
  1. EA: essential agreement; CA: categorical agreement; VME: very major error; ME: major error; miE: minor error; ND: not done
  2. *FDA thresholds for VME, ≤ 2%; ME, < 3%; no criteria for miE; VME and ME thresholds based on adjusted analysis (excluding EA) for CZA due to absence of intermediate breakpoint
  3. **Recalculated minor errors (excluding EA)
\